[Corrections] Correction to Lancet Oncol 2023; 24: 1094–108

Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1094–108—In this Article, 2-year overall survival in the placebo plus abiraterone group shown in figure 2 has been corrected to 65·5% (95% CI 60·5–70·0); in table 2, the value for grade 1–2 anaemia in the olaparib plus abiraterone group should read 134 (34%), grade 3 anaemia in the olaparib plus abiraterone group should read 60 (15%), grade 1–2 fatigue or asthenia in the olaparib plus abiraterone group should read 144 (36%), grade 1–2 fatigue or asthenia in the placebo plus abiraterone group should read 114 (29%), and data for neutropenia were previously erroneously omitted and have now been added.